HOME HELP SUBSCRIBE ARCHIVE SEARCH TABLE OF CONTENTS FEEDBACK EDITORIAL BOARD ABOUT DOC NEWS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goldfarb, B. Search for Related Content PubMed Articles by Goldfarb, B. Social Bookmarking                What's this?

Experimental Diabetes Drug Shows Promise

An experimental "antisense" drug that interferes with the expression of a protein involved with insulin resistance appears to show promise in the treatment of type 2 diabetes, according to the preliminary results of a phase II clinical trial reported at the 65th Scientific Sessions of the American Diabetes Association.

ISIS 113715, developed by Isis Pharmaceuticals of Carlsbad, Calif., is designed to inhibit a target for insulin signaling, PTP-1B, a mediator of insulin resistance that reduces cellular responses to insulin.

For the double-blind phase II trial, ISIS 113715 is being tested at four dose levels—100 mg, 200 mg, 400 mg, and 600 mg per week—for 6 weeks. Preliminary data suggest that 45% of patients achieved a glycated hemoglobin (A1C) level of 7% at the 200-mg dose, compared with 25% of those who received placebo. Studies at the higher doses are still being completed, according to company researchers.

Isis plans on beginning studies of ISIS 113715 in combination with other antidiabetes medications.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Goldfarb, B. Search for Related Content PubMed Articles by Goldfarb, B. Social Bookmarking                What's this?